The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAlpha Growth Regulatory News (ALGW)

Share Price Information for Alpha Growth (ALGW)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 2.10
Bid: 2.00
Ask: 2.20
Change: -0.15 (-6.67%)
Spread: 0.20 (10.00%)
Open: 2.25
High: 2.25
Low: 2.10
Prev. Close: 2.25
ALGW Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Financial Services Company Acquistion

17 Nov 2022 07:00

RNS Number : 6892G
Alpha Growth PLC
17 November 2022
 

The information communicated within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 (as amended). Upon the publication of this announcement, this inside information is now considered to be in the public domain.

 

 

Alpha Growth plc

("Alpha" or the "Company")

Complementary Financial Services Company Acquisition

 

Alpha Growth plc (LSE: ALGW and OTCQB: ALPGF), a leading financial services specialist in the growing life insurance and longevity asset class, is pleased to announce that it has signed a share purchase agreement to acquire Havelet Assignment Company Limited ("Havelet"), a Barbados based financial services company specialising in settlement assignments. This is a strategic acquisition which not only expands Alpha's abilities to accumulate assets under administration but also provides a complementary source of business to Alpha's Providence Life Assurance Company ("Providence").

Alpha expects to complete the acquisition by 30 November 2022 and will make additional announcements in due course once completed. The acquisition of Havelet is not subject to regulatory approval and there are no conditions to completion other than the satisfaction of conditions customary for a transaction of this nature. The terms of the acquisition included the payment to the seller of a nominal sum for the outstanding shares of Havelet and 10% of the net fees generated for a limited time period, by the assets under administration. Havelet currently administers ~$9 million in assigned settlements and generates net profit margins of ~52%. The company is cash flow positive. No shares were issued by Alpha for the acquisition.

Havelet, established in 2012, provides solutions to claimants and attorneys who are awarded settlements through litigation to defer receipt of their settlement on a pre-tax basis. As the settlement obligation is invested on a pre-tax basis and grows on a tax-deferred basis, there is a much larger capital base than if the settlement were received directly by the claimant, taxed, and then invested. The net result is the potential for a higher after-tax sum to be received by the claimant. Havelet is not subject to withholding tax on dividends pursuant to Barbados-US taxation arrangements.

Havelet's clients, established over the past ten years, can customise deferral and payment terms; receive lump sum distributions; and select beneficiaries through annuities purchased and managed by Havelet, typically ranging from 10 to 20 years depending upon the age of the claimant and the settlement type. These annuities will be capable of being issued by Providence, thereby increasing the cross-selling opportunities across the Alpha group of companies. The annuities aim to provide a long-term independent stream of revenue for both Havelet and Providence.

Going forward, Alpha plans to increase the marketing of Havelet's solutions to its established clientele and broader legal community in the US with a view to materially increasing the assets under administration.

Alpha's Non-Executive Director Jason Sutherland stated: "I have been in the annuity sector for over 20 years and very familiar with the settlement assignment business. It's a consistently growing field given the amount of civil litigation in the US and awarding of large claims. Havelet is an ideal acquisition for Alpha as it will generate service fees on its own level and opens a channel for Providence to issue annuities and grow its fee-based assets under administration."

Gobind Sahney, Alpha's Executive Chairman added: "Havelet is a small but important acquisition for Alpha Growth and one which provides significant additional opportunities to grow AUM within both Havelet and Providence. As part of our build and buy strategy, we continue to actively progress our acquisition pipeline and will update shareholders on progress when appropriate."

** ENDS **

For more information, please visit www.algwplc.com or contact the following:

 

Alpha Growth plc

+44 (0) 20 3959 8600

Gobind Sahney, Executive Chairman

info@algwplc.com

 

Allenby Capital Limited

+44 (0) 20 3328 5656

Amrit Nahal (Sales and Corporate Broking)

Nick Athanas / Piers Shimwell (Corporate Finance)

 

UK Investor Relations - Mark Treharne

ir@algwplc.com

 

About Alpha Growth plc

Specialist in Longevity Assets

Alpha Growth plc is a financial advisory business providing specialist consultancy, advisory, and supplementary services to institutional and qualified investors globally in the multi-billion dollar market of longevity assets. Building on its well-established network, the Alpha Growth group has a unique position in the longevity asset services and investment business, as a listed entity with global reach. The group's strategy is to expand its advisory and business services via acquisitions and joint ventures in the UK and the US to attain commercial scale and provide holistic solutions to alternative institutional investors who are in need of specialised skills and unique access to deploy their financial resource in longevity assets.

Longevity Assets and Non-correlation

As a longevity asset, it is non-correlated to the real estate, equity capital and commodity markets. Its value is a function of time because as time passes the value gets closer to the face value of the policy. Hence creating a steady increase in the net asset value of the investment. This makes it highly attractive to investors wishing to counteract volatility within an investment portfolio and add yield.

Note: The Company only advises on and manages Longevity Assets that originate in the USA where the structured and life settlement market is highly regulated.

Forward Looking Statements Disclaimer

Certain statements, beliefs and opinions in this document are forward-looking, which reflect the Company's or, as appropriate, the Company's directors' current expectations and projections about future events. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. Forward-looking statements contained in this document regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. The Company does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. You should not place undue reliance on forward- looking statements, which speak only as of the date of this document. Readers should not treat the contents of this document as advice relating to legal, taxation or investment matters, and are to make their own assessments concerning these and other consequences, including the merits of information and the risks. Readers of this announcement are advised to conduct their own due diligence and agree to be bound by the limitations of this disclaimer.

Important Notice

The content of this announcement has not been approved by an authorised person within the meaning of the Financial Services and Markets Act 2000 (FSMA). This announcement has been issued by and is the sole responsibility of the Company. The information in this announcement is subject to change.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
ACQFFDFUMEESESF
Date   Source Headline
10th Feb 20208:00 amRNSResult of AGM
31st Dec 20197:00 amRNSPublication of the 2019 Annual Report
17th Dec 20197:00 amRNSTrack Record Review, Placing & Total Voting Rights
2nd Dec 20197:00 amRNSAdvancement of Warehousing SPV and Subscription
11th Nov 20197:00 amRNSAppointments and Board changes
20th Sep 201911:46 amRNSSecond Price Monitoring Extn
20th Sep 201911:45 amRNSPrice Monitoring Extension
18th Sep 20193:31 pmRNSAlpha Growth - Holding(s) in Company
12th Aug 20197:00 amRNSHolding(s) in Company
15th Jul 20197:00 amRNSCorporate Update
2nd Jul 20199:14 amRNSHolding(s) in Company
5th Jun 20197:00 amRNSIssue of Equity & TVR
16th May 201912:00 pmRNSHolding(s) in Company
10th May 20192:16 pmRNSPublication of Prospectus
3rd May 201911:05 amRNSSecond Price Monitoring Extn
3rd May 201911:00 amRNSPrice Monitoring Extension
30th Apr 20197:20 amRNSProposed Placing
30th Apr 20197:00 amRNSBlackOak Alpha Growth Fund Launch
29th Apr 20194:00 pmRNSInterim Results
18th Apr 20192:00 pmRNSPrice Monitoring Extension
29th Mar 20192:28 pmRNSHolding(s) in Company
6th Mar 20197:00 amRNSBoard Changes
4th Mar 201910:10 amRNSResult of AGM
4th Mar 20197:00 amRNSCorporate Update
1st Mar 20197:00 amRNSAcquisition of Colva
20th Feb 201910:28 amRNSIssue of Equity
13th Feb 20197:00 amRNSAlpha Growth Investor Meeting
7th Feb 20197:00 amRNSAlpha Growth - Notice of Annual General Meeting
30th Jan 20197:00 amRNSAcquisition: Completion of ALM Acquisition
24th Dec 201810:52 amRNSFinal Results
21st Nov 20187:00 amRNSSL Investment Management Joint Venture
15th Nov 201811:36 amRNSHolding(s) in Company
24th Sep 20181:59 pmRNSHolding(s) in Company
17th Sep 20184:40 pmRNSSecond Price Monitoring Extn
17th Sep 20184:35 pmRNSPrice Monitoring Extension
17th Sep 20182:05 pmRNSSecond Price Monitoring Extn
17th Sep 20182:00 pmRNSPrice Monitoring Extension
17th Sep 201812:18 pmRNSHolding(s) in Company
17th Sep 20187:00 amRNSIssue of Equity and Director/PDMR Dealing
4th Sep 20185:14 pmRNSHolding(s) in Company
30th Aug 201812:16 pmRNSHolding(s) in Company
24th Aug 201812:59 pmRNSNotification of Major Holdings
18th Jul 20187:00 amRNSAcquisition of ALM
13th Jun 20187:00 amRNSHolding(s) in Company
8th Jun 20187:00 amRNSEngagement of Devonshire Warwick, Investor Event
1st Jun 20187:00 amRNSAppointment of Chief Operating Officer
11th May 20184:03 pmRNSHolding(s) in Company
30th Apr 20181:00 pmRNSInterim results
12th Mar 20182:13 pmRNSAppointment of Corporate Advisor and Broker
6th Feb 20187:00 amRNSLaunch of Innovative Hybrid Product

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.